Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 3NET 1Genitourinary 1Dermatologic 1

Conditions

Pituitary Neoplasms 7Pituitary ACTH Hypersecretion 3Acromegaly 2Recurrence 1Prostatic Neoplasms 1Prolactinoma 1Neuroendocrine Tumors 1Neoplasms 1Melanoma 1Dumping Syndrome 1Brain Neoplasms 1Adrenocortical Hyperfunction 1Adenoma 1ACTH-Secreting Pituitary Adenoma 1

Interventions

relacorilant 3Mifepristone 3Corlux 3Cabergoline 3pasireotide 2fimepinostat 1corticorelin ovine 1Tissue Banks 1Rosiglitazone 1Perceived Stress Scale 1Magnetic Resonance Spectroscopy 1Deamino Arginine Vasopressin 1Biomarkers 14-amino-4'-hydroxylaminodiphenylsulfone 12-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Pituitary ACTH Hypersecretion × Cabergoline × Endocrine × Clear all
NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUP

Phase 4 Completed
337 enrolled 8 charts
DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

NCT01915303 2020-09-18

Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease

Novartis

Phase 2 Terminated
68 enrolled 25 charts
Endocrine

Adrenocortical Hyperfunction, Pituitary Neoplasms, Pituitary ACTH Hypersecretion

NCT00889525 2009-04-29

Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor

Seth Gordhandas Sunderdas Medical College

Phase 3 Completed
Endocrine

Pituitary ACTH Hypersecretion, ACTH-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡